{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:53:51Z","timestamp":1782150831879,"version":"3.54.5"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>ClinicalTrials.gov captures registered hair-loss trials across the full research lifecycle, including ongoing, discontinued, and unpublished studies. We used this registry to describe how the hair-loss clinical trial landscape has evolved from 2015 to 2025, focusing on trial volume, geography, indications, intervention types, outcome assessment, and sponsorship.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a descriptive cross-sectional meta-research analysis of hair-loss\u2013related interventional studies registered on\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      (2015\u20132025). Trials were categorized by recruitment status, country\/region, sex, and age eligibility, primary indication, intervention modality, primary outcome assessment approach, and sponsor type. We summarized distributions and temporal trends using descriptive statistics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 514 hair-loss trials, with registrations increasing over time, particularly after 2020. Activity was global but concentrated in select regions, especially North America, and most trials were completed or recruiting. Androgenetic alopecia and alopecia areata predominated; pharmacologic therapies were most common overall, with greater therapeutic diversity in androgenetic alopecia. Outcome reporting was heterogeneous, objective imaging was infrequent, and sponsorship was divided between industry and academic\/non-profit institutions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This registry-based analysis nevertheless delineates a rapidly expanding yet structurally uneven landscape of hair-loss clinical research, marked by geographic concentration, therapeutic clustering, and variability in outcome specification. By systematically mapping trial activity, indications, modalities, sponsorship, and completion patterns, the study reframes attention from individual therapies to the broader architecture of evidence production. These findings underscore the need for standardized outcomes, broader population representation, and closer alignment between research investment and clinical need in hair-loss disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1821858","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:41:41Z","timestamp":1782150101000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A decade of hair-loss clinical trials: a registry-based analysis of studies registered on ClinicalTrials.gov"],"prefix":"10.3389","volume":"13","author":[{"given":"Alexa D.","family":"Parra-Guerra","sequence":"first","affiliation":[{"name":"Research Unit, Renati Innovation, Onkimia","place":["Guadalajara, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"S\u00e1nchez-Due\u00f1as","sequence":"additional","affiliation":[{"name":"Dermatologic Institute of Jalisco \u201cDr. Jos\u00e9 Barba Rubio\u201d, University of Guadalajara","place":["Guadalajara, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Le\u00f3n","family":"Quintero-Loreto","sequence":"additional","affiliation":[{"name":"Dermatologic Institute of Jalisco \u201cDr. Jos\u00e9 Barba Rubio\u201d, University of Guadalajara","place":["Guadalajara, Mexico"]},{"name":"Hospital San Javier","place":["Guadalajara, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyanira G.","family":"Quino\u00f1es-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Dermatologic Institute of Jalisco \u201cDr. Jos\u00e9 Barba Rubio\u201d, University of Guadalajara","place":["Guadalajara, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Moreno-Alanis","sequence":"additional","affiliation":[{"name":"Dermatologic Institute of Jalisco \u201cDr. Jos\u00e9 Barba Rubio\u201d, University of Guadalajara","place":["Guadalajara, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah K. Sevilla","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Trico and Derm Clinc","place":["San Pedro Garza Garc\u00eda, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar J. Ramos","family":"Cavazos","sequence":"additional","affiliation":[{"name":"Hospital Universitario \u201cDr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d de la UANL","place":["Monterrey, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Guti\u00e9rrez","family":"Mendoza","sequence":"additional","affiliation":[{"name":"AROAH Denter Dermatolog\u00eda","place":["Tijuana, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar D.","family":"Villarreal-Villarreal","sequence":"additional","affiliation":[{"name":"ITESM Monterrey","place":["Nuevo Le\u00f3n, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Chejfec-Ciociano","sequence":"additional","affiliation":[{"name":"Research Unit, Renati Innovation, Onkimia","place":["Guadalajara, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.3390\/jcm12093259","article-title":"Recent advances in understanding of the etiopathogenesis, diagnosis, and management of hair loss diseases","volume":"12","author":"Kinoshita-Ise","year":"2023","journal-title":"J Clin Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/17425247.2020.1723543","article-title":"Novel drug delivery approaches for the management of hair loss","volume":"17","author":"Alsalhi","year":"2020","journal-title":"Expert Opin Drug Deliv."},{"key":"B3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.5021\/ad.25.042","article-title":"Updates in treatment for androgenetic alopecia","volume":"37","author":"Shin","year":"2025","journal-title":"Ann Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjd.14497","article-title":"Alopecia areata and health-related quality of life: a systematic review and meta-analysis","volume":"175","author":"Rencz","year":"2016","journal-title":"Br J Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jamadermatol.2021.2196","article-title":"Health-related quality of life, depression, and self-esteem in patients with androgenetic alopecia: a systematic review and meta-analysis","volume":"157","author":"Huang","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40257-022-00730-y","article-title":"What's new in therapy for male androgenetic alopecia?","volume":"24","author":"Saceda-Corralo","year":"2023","journal-title":"Am J Clin Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40257-023-00808-1","article-title":"Alopecia areata: current treatments and new directions","volume":"24","author":"Dahabreh","year":"2023","journal-title":"Am J Clin Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13287-024-03801-5","article-title":"Clinical and preclinical approach in AGA treatment: a review of current and new therapies in the regenerative field","volume":"15","author":"Pozo-P\u00e9rez","year":"2024","journal-title":"Stem Cell Res Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1186\/s13063-022-06569-2","article-title":"Update on the clinical trial landscape: analysis of ClinicalTrials.gov registration data, 2000-2020","volume":"23","author":"Gresham","year":"2022","journal-title":"Trials"},{"key":"B10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.5195\/jmla.2023.1758","article-title":"Recognizing the value of meta-research and making it easier to find","volume":"111","author":"Stevens","year":"2023","journal-title":"J Med Libr Assoc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jaad.2021.02.078","article-title":"Characteristics of dermatology clinical trials 2007-2018: insights from a systematic analysis of ClinicalTrials","volume":"86","author":"Jia","year":"2022","journal-title":"gov J Am Acad Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13643-022-02096-y","article-title":"Meta-research evaluating redundancy and use of systematic reviews when planning new studies in health research: a scoping review","volume":"11","author":"Lund","year":"2022","journal-title":"Syst Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/S0140-6736(15)00307-4","article-title":"Increasing value and reducing waste in biomedical research: who's listening?","volume":"387","author":"Moher","year":"2016","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0187865","DOI":"10.1371\/journal.pone.0187865","article-title":"Inconsistent selection of outcomes and measurement devices found in shoulder arthroplasty research: an analysis of studies on ClinicalTrials.gov","volume":"12","author":"Sims","year":"2017","journal-title":"PLoS One."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e081477","DOI":"10.1136\/bmj-2024-081477","article-title":"SPIRIT 2025 statement: updated guideline for protocols of randomised trials","volume":"389","author":"Chan","year":"2025","journal-title":"BMJ."},{"key":"B16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13555-022-00711-3","article-title":"Defining severity in alopecia areata: current perspectives and a multidimensional framework","volume":"12","author":"King","year":"2022","journal-title":"Dermatol Ther (Heidelb)."},{"key":"B17","unstructured":"Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims\n          \n          2009"},{"key":"B18","article-title":"Advancing equity and inclusion in global dermatology research: strategies and methodological considerations","author":"Li","year":"","journal-title":"J Invest Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e2113749","DOI":"10.1001\/jamanetworkopen.2021.13749","article-title":"Analysis of Female enrollment and participant sex by burden of disease in US clinical trials between 2000 and 2020","volume":"4","author":"Steinberg","year":"2021","journal-title":"JAMA Netw Open."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2524440","DOI":"10.1001\/jamanetworkopen.2025.24440","article-title":"Nonregistration, discontinuation, and nonpublication of randomized trials: a systematic review","volume":"8","author":"Speich","year":"2025","journal-title":"JAMA Netw Open."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2350688","DOI":"10.1001\/jamanetworkopen.2023.50688","article-title":"Publication of results of registered trials with published study protocols, 2011-2022","volume":"7","author":"Vorland","year":"2024","journal-title":"JAMA Netw Open."},{"key":"B22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ijcard.2017.06.020","article-title":"Discontinuation and non-publication of clinical trials in cardiovascular medicine","volume":"244","author":"Roddick","year":"2017","journal-title":"Int J Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"104317","DOI":"10.1016\/j.drudis.2025.104317","article-title":"Unlocking disease insights to facilitate drug development: pharmaceutical industry-academia collaborations in inflammation and immunology","volume":"30","author":"Peeva","year":"2025","journal-title":"Drug Discov Today."},{"key":"B24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/cpt.2819","article-title":"Enhancing diversity and inclusion in clinical trials","volume":"113","author":"Corneli","year":"2023","journal-title":"Clin Pharmacol Ther."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1821858\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:41:45Z","timestamp":1782150105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1821858\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":24,"alternative-id":["10.3389\/fmed.2026.1821858"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1821858","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1821858"}}